U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
LEIDEN, the Netherlands, Dec. 27, 2017 -- ProQR Therapeutics N.V.(Nasdaq:PRQR), today announced that an Extraordinary General Meeting of Shareholders will be held on Monday, February 19, 2018, at 16:00 CET, at the offices of the Company at Zernikedreef 9, 2333CK, Leiden, the Netherlands.
All relevant documents and information for the meeting, including the notice and agenda, are or will be made available in the ‘Investor Relations’section of ProQR’s website (www.proqr.com) under ‘Financial Information’. The documents will also be made available on the SEC’s website at www.sec.gov.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as cystic fibrosis, Leber’s congenital amaurosis 10 and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*
ProQR Therapeutics N.V.:
Investor Contact:
Bonnie Ortega
T: +1 858 245 3983
[email protected]
